Carbimazole is thiourea anti-thyroid drugs that act by blocking the production of thyroid hormones. It is used in the management of hyperthyroidism, including the treatment of Grave’s disease, the preparation of hyperthyroid patients for thyroidectomy, uses as an adjunct to radio-iodine therapy and the treatment for thyroid storm.
Each tablet contains:
Carbimazole …. 20 mg
The anti-thyroid activity of Carbimazole is dependent upon conversion of Carbimazole to methimazole (Thiamazole) in the body. Carbimazole is rapidly and completely metabolized to methimazole (Thiamazole) in the body. Carbimazole and other thiourea anti-thyroid drug are rapidly absorbed from the gastrointestinal tract with peak plasma concentrations occuring about 1 to 2 hour following administration by mouth.
They are concentrated in the thyroid drug, and since their duration of action is more closely related to the intrathyroidal drug concentration than their plasma half-life, this result in the prolongation of anti-thyroid activity such that daily single doses are possible.
DOSAGE AND ADMINISTRATION:
Carbimazole is given by mouth typically in the an initial dosage of 15-40 mg daily. It has often been given in divided daily doses but once-daily administration is also possible. When the smallest amount that will maintain the euthyroid state. Typical maintenance doses are 5 to 15 mg daily. Alternatively, the dose may be continued at the initial level in combination with supplement thyroxin as a clocking replacement regimen. Either form of maintenance treatment is usually continued for at lease a year, and often for 18 months. Children maybe given an initial dose of 250 ug per kg body-weight three times daily, adjusted according to response: treatment in children should be by a specialist.
Adverse effects from Carbimazole and other thiourea anti-thyroid drugs occur most frequently during the first 8 weeks of treatment. The most common minor adverse effects are nausea and vomiting, gastric discomfort, headache, arthalgia, skin rashes and pruritus. Hair loss has also been reported.
Bone marrow depression may occur and mild leukopenia is common. Rarely, agranulocytosis can develop and this is the most serious adverse reaction associated with this class of drug. Aplastic anemia or isolated thrombocytopenia have been reported.
Bonemarrow depression may occur and mild leucopenia is common. Rarely, agranulocytosis can develop and this is the most serious adverse reaction associated with this class of drug. Aplastic anemmia or isolated thrombocytopenia have been reported. Other adverse effects sometimes observed with thiourea anti-thyroid compound include fever, a lupus-like syndrome, myopathy vasculitis and nephritis, and taste disturbances. High doses in pregnancy may result in fetal hypothyroidism and goiter.
1. Neutropenia and agranulocytosis are idiosyncratic reactions to all the thiomide drugs.
2. Carbimazolemay induce bone marrow supression.
Carbimazole is contraindicated in patients with a history of adverse reactions to Carbimazole.
Increased sensitivity to warfarin in hyperthyroid state. DOes adjustmentis required when patient rendered euthyroid.
Excessive doses of anthyroid drugs may cause hypothyroidism and goitre.
Alu-Alu Blister Pack X 10′s (Box of 50′s)